GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
US4165370A
(en)
|
1976-05-21 |
1979-08-21 |
Coval M L |
Injectable gamma globulin
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼbmp−8231およびその製造法
|
EP0018609B1
(fr)
|
1979-04-30 |
1983-09-21 |
Hoechst Aktiengesellschaft |
Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
EP0083619A1
(fr)
|
1981-07-17 |
1983-07-20 |
Nordisk Insulinlaboratorium |
Preparation therapeutique d'insuline aqueuse stable et son procede de preparation
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
CA1244347A
(fr)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Formule d'insuline stabilisee
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
EP0166971B1
(fr)
|
1984-06-09 |
1990-02-28 |
Hoechst Aktiengesellschaft |
Préparations d'insuline, procédé pour leur fabrication et leur application
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
IL78425A
(en)
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
CA1275922C
(fr)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Traitement du cancer
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
WO1988006599A1
(fr)
|
1987-02-25 |
1988-09-07 |
Novo Industri A/S |
Nouveaux derives d'insuline
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
AU641631B2
(en)
|
1988-12-23 |
1993-09-30 |
Novo Nordisk A/S |
Human insulin analogues
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
PT93057B
(pt)
|
1989-02-09 |
1995-12-29 |
Lilly Co Eli |
Processo para a preparacao de analogos da insulina
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
DE69024953T3
(de)
|
1989-05-04 |
2005-01-27 |
Southern Research Institute, Birmingham |
Einkapselungsverfahren
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
GR1005153B
(el)
|
1989-08-29 |
2006-03-13 |
The General Hospital Corporation |
Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
AU7880991A
(en)
|
1990-05-10 |
1991-11-27 |
Novo Nordisk A/S |
A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
CA2038597A1
(fr)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
Methode et preparation pharmaceutique pour le soulagement de la douleur
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
EP0600372B1
(fr)
|
1992-12-02 |
1997-02-05 |
Hoechst Aktiengesellschaft |
Procédé de préparation de proinsuline à ponts de cystine liés correctment
|
PL310007A1
(en)
|
1992-12-18 |
1995-11-13 |
Lilly Co Eli |
Insulin analogues
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
EP0705275B1
(fr)
|
1993-06-21 |
1999-02-03 |
Novo Nordisk A/S |
Cristaux d'insuline asp-b28
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
DE69429820T3
(de)
|
1993-11-19 |
2013-02-28 |
Alkermes Controlled Therapeutics, Inc. |
Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
AU689217B2
(en)
|
1994-03-07 |
1998-03-26 |
Novartis Ag |
Methods and compositions for pulmonary delivery of insulin
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
EP0779806B2
(fr)
|
1994-09-09 |
2008-04-16 |
Takeda Pharmaceutical Company Limited |
Preparation a liberation prolongee renfermant un sel metal de peptide
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
US5766582A
(en)
|
1994-10-11 |
1998-06-16 |
Schering Corporation |
Stable, aqueous alfa interferon solution formulations
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
YU18596A
(sh)
|
1995-03-31 |
1998-07-10 |
Eli Lilly And Company |
Analogne formulacije monomernog insulina
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
CA2223272A1
(fr)
|
1995-05-05 |
1996-11-07 |
Ronald Eugene Chance |
Insuline monocatenaire a bioactivite elevee
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
AU6011496A
(en)
|
1995-06-08 |
1997-01-09 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
ATE316100T1
(de)
|
1996-06-05 |
2006-02-15 |
Roche Diagnostics Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
DE69708121T3
(de)
|
1996-06-20 |
2012-05-16 |
Novo Nordisk A/S |
Halogenid-enthaltende insulinzubereitungen
|
IL127365A0
(en)
|
1996-06-20 |
1999-10-28 |
Novo Nordisk As |
Insulin preparations containing carbohydrates
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
CA2262647C
(fr)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methodes de regulation de la motilite gastro-intestinale
|
AU752411B2
(en)
|
1996-08-13 |
2002-09-19 |
Genentech Inc. |
Formulation
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
DE69737479T4
(de)
|
1996-08-30 |
2010-05-06 |
Novo Nordisk A/S |
Glp-1 derivate
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
ES2425559T5
(es)
|
1997-01-07 |
2018-02-02 |
Amylin Pharmaceuticals, Llc |
Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
WO1998035033A1
(fr)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides codant la proexendine, et procedes et utilisations correspondants
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
CN1259142A
(zh)
|
1997-03-20 |
2000-07-05 |
诺沃挪第克公司 |
用于肺部的无锌胰岛素结晶组合物
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
DK0999853T3
(da)
|
1997-06-13 |
2003-04-22 |
Genentech Inc |
Stabiliseret antostofformulering
|
CO4750643A1
(es)
|
1997-06-13 |
1999-03-31 |
Lilly Co Eli |
Formulacion estable de la insulina que contiene l-arginina y protamina
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
PT1019077E
(pt)
|
1997-08-08 |
2008-02-21 |
Amylin Pharmaceuticals Inc |
Novos compostos agonistas de exendina
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
IL134901A0
(en)
|
1997-10-24 |
2001-05-20 |
Lilly Co Eli |
Insoluble insulin compositions
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
CA2309955A1
(fr)
|
1997-11-12 |
1999-05-20 |
Alza Corporation |
Procede permettant de reduire l'association spontanee de polypeptides
|
JP2003522721A
(ja)
|
1997-11-14 |
2003-07-29 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規なエキセンジンアゴニスト化合物
|
DK1032587T4
(da)
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
JP2001525371A
(ja)
|
1997-12-05 |
2001-12-11 |
イーライ・リリー・アンド・カンパニー |
Glp−1製剤
|
ATE290877T1
(de)
|
1998-01-09 |
2005-04-15 |
Novo Nordisk As |
Stabilisierte insulin-zubereitungen
|
ATE366115T1
(de)
|
1998-02-13 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Inotropische und diuretische effekte von exendin und glp-1
|
AU741037B2
(en)
|
1998-02-23 |
2001-11-22 |
Neurocrine Biosciences, Inc. |
Methods for treatment of diabetes using peptide analogues of insulin
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
JP4394279B2
(ja)
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
EP1083930B1
(fr)
|
1998-06-05 |
2008-11-12 |
Nutrinia Limited |
Preparation pour nourrissons enrichie en insuline
|
WO2000020592A1
(fr)
|
1998-10-07 |
2000-04-13 |
Medical College Of Georgia Research Institute, Inc. |
Peptide glucodependant insulinotrope utilise comme hormone osteotrope
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
CN1210058C
(zh)
|
1998-10-16 |
2005-07-13 |
诺沃挪第克公司 |
用于肺送递的稳定的浓缩胰岛素制剂
|
ES2177324T3
(es)
|
1998-10-16 |
2002-12-01 |
Novo Nordisk As |
Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
DE69914934T2
(de)
|
1998-11-18 |
2005-01-05 |
Novo Nordisk A/S |
Stabile, wässrige insulin-präparate ohne phenol und cresol
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
CA2356706C
(fr)
|
1999-01-14 |
2014-09-30 |
Amylin Pharmaceuticals, Inc. |
Nouvelles formulations d'agonistes de l'exendine et modes d'administration
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
CA2372214A1
(fr)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Exendines modifiees et agonistes de l'exendine
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6978471B1
(en)
|
1999-05-25 |
2005-12-20 |
Thomson Licensing S.A. |
System for acquiring and processing broadcast programs and program guide data
|
WO2000074736A1
(fr)
|
1999-06-04 |
2000-12-14 |
Delrx Pharmaceutical Corporation |
Formulations comprenant des particules deshydratees d'agents pharmaceutiques et leur procede de preparation
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
AU5760900A
(en)
|
1999-06-25 |
2001-01-31 |
Minimed, Inc. |
Multiple agent diabetes therapy
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(fr)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides abaissant le taux de glucose sanguin
|
CA2383233C
(fr)
|
1999-09-21 |
2010-06-08 |
Rtp Pharma Inc. |
Compositions particulaires, a surface modifiee, de substances biologiquement actives
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
CN100389821C
(zh)
|
1999-10-04 |
2008-05-28 |
希龙公司 |
稳定化的含多肽的液体药物组合物
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
HU229352B1
(en)
|
1999-11-03 |
2013-11-28 |
Bristol Myers Squibb Co |
Medicament comprising the combination of metformin and glyburide
|
JP2003523972A
(ja)
|
1999-12-16 |
2003-08-12 |
イーライ・リリー・アンド・カンパニー |
安定性が改良されたポリペプチド組成物
|
EP1523993A1
(fr)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Compositions contenant un polypeptide et ayant une plus grande stabilité
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
AU2353701A
(en)
|
2000-01-11 |
2001-07-24 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
AU2001220765A1
(en)
|
2000-01-24 |
2001-07-31 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
AU2001264789A1
(en)
|
2000-06-08 |
2001-12-17 |
Eli Lilly And Company |
Protein powder for pulmonary delivery
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US20030212248A1
(en)
|
2000-07-12 |
2003-11-13 |
Furman Thomas Charles |
Process to increase protein stability
|
EP1326630B1
(fr)
|
2000-09-18 |
2008-05-28 |
Sanos Bioscience A/S |
Utilisation de peptides glp-2
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
US6852694B2
(en)
|
2001-02-21 |
2005-02-08 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
US20020177151A1
(en)
|
2001-02-26 |
2002-11-28 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
EP1377608B1
(fr)
|
2001-04-02 |
2009-09-16 |
Novo Nordisk A/S |
Precurseurs de l'insuline et procede de preparation
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
AU2002318159A1
(en)
|
2001-06-29 |
2003-03-03 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
EP2022505B1
(fr)
|
2001-07-31 |
2011-12-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendine-4, analogues de peptides et utilisations associées
|
EP1432430A4
(fr)
|
2001-08-28 |
2006-05-10 |
Lilly Co Eli |
Pre-melanges de polypeptide glp-1 et d'insuline basale
|
WO2003035051A2
(fr)
|
2001-10-19 |
2003-05-01 |
Inhale Therapeutic Systems, Inc. |
Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
|
US20050123509A1
(en)
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
WO2003044210A2
(fr)
|
2001-11-19 |
2003-05-30 |
Novo Nordisk A/S |
Elaboration de composes insuliniques
|
EP1455815A4
(fr)
|
2001-12-19 |
2006-11-02 |
Millennium Pharm Inc |
Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
|
EP1545460A4
(fr)
|
2001-12-20 |
2005-11-16 |
Lilly Co Eli |
Molecule d'insuline a duree d'action prolongee
|
BR0215216A
(pt)
|
2001-12-21 |
2004-11-16 |
Novo Nordisk Healthcare Ag |
Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
WO2003066084A1
(fr)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Utilisation d'un compose glp-1 dans le traitement de patients gravement atteints
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
TW200305415A
(en)
*
|
2002-03-22 |
2003-11-01 |
Novartis Ag |
Combination of organic compounds
|
JP2005526126A
(ja)
|
2002-05-07 |
2005-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
|
ES2360182T3
(es)
|
2002-05-07 |
2011-06-01 |
Novo Nordisk A/S |
Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
AU2003243929B2
(en)
|
2002-07-04 |
2009-06-04 |
Zp Holding Spv K/S |
GLP-1 and methods for treating diabetes
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
CA2499983A1
(fr)
|
2002-09-27 |
2004-04-08 |
Martek Biosciences Corporation |
Regulation glycemique amelioree dans le prediabete et/ou le diabete de type ii au moyen de l'acide docosahexaenoique
|
KR20050083713A
(ko)
|
2002-10-02 |
2005-08-26 |
질랜드 파마 에이/에스 |
안정화된 엑센딘-4 화합물
|
WO2004045592A2
(fr)
|
2002-11-20 |
2004-06-03 |
Neuronova Ab |
Composes et methodes permettant d'augmenter la neurogenese
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
EP1569682A2
(fr)
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
WO2004078196A1
(fr)
|
2003-03-04 |
2004-09-16 |
The Technology Development Company Ltd. |
Composition d'insuline a administration orale et ses procedes de production et d'utilisation.
|
JP2007523842A
(ja)
|
2003-03-11 |
2007-08-23 |
ノボ ノルディスク アクティーゼルスカブ |
酸安定化されたインスリンを含有する薬学的製剤
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
CA2518776A1
(fr)
|
2003-04-29 |
2004-11-11 |
Eli Lilly And Company |
Analogues de l'insuline ayant une action prolongee
|
PL1633390T3
(pl)
|
2003-06-03 |
2012-06-29 |
Novo Nordisk As |
Stabilizowane kompozycje farmaceutyczne peptydu glp-1
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
US20050106147A1
(en)
|
2003-08-29 |
2005-05-19 |
Robert Jordan |
Method of promoting graft survival with anti-tissue factor antibodies
|
EP1663295A2
(fr)
|
2003-09-01 |
2006-06-07 |
Novo Nordisk A/S |
Formulations de peptides stables
|
WO2005023291A2
(fr)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
|
EP1667724A2
(fr)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Nouvelles etiquettes d'affinite pour les proteines plasmiques
|
ATE525083T1
(de)
|
2003-11-13 |
2011-10-15 |
Novo Nordisk As |
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
US20050201978A1
(en)
|
2003-11-17 |
2005-09-15 |
Lipton James S. |
Tumor and infectious disease therapeutic compositions
|
EP1699629B1
(fr)
|
2003-12-22 |
2010-10-06 |
Novo Nordisk A/S |
Contenant en plastique transparent, souple et impermeable, destine a stocker des liquides pharmaceutiques
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
WO2005067898A2
(fr)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
US20080248999A1
(en)
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
MXPA06011425A
(es)
|
2004-03-31 |
2007-03-12 |
Johnson & Johnson |
Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
EP1758597B1
(fr)
|
2004-05-20 |
2012-09-12 |
Diamedica Inc. |
Utilisation de combinaisons medicamenteuses pour traiter la resistance a l'insuline
|
EP1750750B1
(fr)
|
2004-06-01 |
2012-02-01 |
Ares Trading S.A. |
Procede de stabilisation de proteines
|
WO2006012226A2
(fr)
|
2004-06-24 |
2006-02-02 |
Incyte Corporation |
Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques
|
EP1906991A2
(fr)
|
2004-06-28 |
2008-04-09 |
Novo Nordisk A/S |
Methodes de traitement du diabete
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
EP2248531A1
(fr)
|
2004-08-03 |
2010-11-10 |
Emisphere Technologies, Inc. |
Combinaison orale antidiabétique d'insuline-biguanide
|
CN101010425B
(zh)
|
2004-08-13 |
2010-05-26 |
霍夫曼-拉罗奇有限公司 |
多肽的c-末端修饰
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
TW200612991A
(en)
|
2004-09-07 |
2006-05-01 |
Chugai Pharmaceutical Co Ltd |
Process for producing water-soluble hyaluronic acid modification
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
JP2008513384A
(ja)
|
2004-09-17 |
2008-05-01 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−2組成物
|
EP1814581B1
(fr)
|
2004-11-12 |
2016-03-16 |
Novo Nordisk A/S |
Preparations stables de peptides comprenant un analogue du glp-1 acyle et une insuline basale
|
WO2006051110A2
(fr)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Formulations stables de peptides
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
EP1843788A4
(fr)
|
2004-12-22 |
2009-11-18 |
Centocor Ortho Biotech Inc |
Agonistes glp-1, compositions, procédés et utilisations
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
CA2602249C
(fr)
|
2005-04-08 |
2012-07-10 |
Amylin Pharmaceuticals, Inc. |
Formulations de peptides et de proteines ayant une meilleure stabilite
|
JP5235661B2
(ja)
|
2005-05-25 |
2013-07-10 |
ノボ・ノルデイスク・エー/エス |
安定化ポリペプチド製剤
|
US8546326B2
(en)
|
2005-06-06 |
2013-10-01 |
Camurus Ab |
Glp-1 analogue formulations
|
EP1948161B1
(fr)
|
2005-06-27 |
2012-01-04 |
Newtree Co., Ltd. |
Methode de prevention et de traitement a l'aide de macelignan d'etats medies par le ppar
|
WO2007006307A2
(fr)
|
2005-07-07 |
2007-01-18 |
Aditech Pharma Ab |
Nouveaux sels de monoalkylesters d'acide fumarique et leur utilisation pharmaceutique
|
EP1971362B1
(fr)
|
2005-08-19 |
2014-12-03 |
Amylin Pharmaceuticals, LLC |
Exendin pour le traitement du diabete et la reduction de poids corporel
|
JP2009507050A
(ja)
|
2005-09-08 |
2009-02-19 |
ガストロテック・ファルマ・アクティーゼルスカブ |
胆道ジスキネジーおよび/または胆道痛/不快の治療のためのglp−1分子の使用
|
KR101304958B1
(ko)
|
2005-09-14 |
2013-09-17 |
에프. 호프만-라 로슈 아게 |
트립신 변이체에 의한 인슐린 전구체의 절단
|
WO2007035665A1
(fr)
|
2005-09-20 |
2007-03-29 |
Novartis Ag |
Utilisation d’un inhibiteur de la ddp-iv en vue de réduire les crises d’hypoglycémie
|
ES2369046T3
(es)
*
|
2005-09-20 |
2011-11-24 |
Novartis Ag |
Uso de un inhibidor dpp-iv para reducir acontecimientos hipoglucémicos.
|
EP1945142B1
(fr)
|
2005-09-26 |
2013-12-25 |
Medtronic, Inc. |
Valve cardiaque prothétique et valvules veineuses
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2007044867A2
(fr)
|
2005-10-11 |
2007-04-19 |
Huntington Medical Research Institutes |
Agents d'imagerie et leurs procédés d'utilisation
|
JP5030960B2
(ja)
|
2005-10-24 |
2012-09-19 |
ネステク ソシエテ アノニム |
食物繊維製剤及び投与方法
|
CN101309668A
(zh)
|
2005-11-30 |
2008-11-19 |
健乐克斯医药公司 |
经口吸收的药物制剂和用药方法
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
WO2007075534A2
(fr)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Conjugues polymeres de glp-1
|
WO2007081792A2
(fr)
|
2006-01-05 |
2007-07-19 |
University Of Utah Research Foundation |
Procedes et compositions associees pour l'amelioration de proprietes d'agents pharmacologiques ciblant le systeme nerveux
|
WO2007081824A2
(fr)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Protéines résistantes à la fibrillation
|
FR2896157B1
(fr)
*
|
2006-01-13 |
2008-09-12 |
Merck Sante Soc Par Actions Si |
Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
|
WO2007082381A1
(fr)
|
2006-01-20 |
2007-07-26 |
Diamedica Inc. |
Compositions contenant (s)-béthanéchol et leur utilisation pour traiter la résistance à l'insuline, le diabète de type 2, l'intolérance au glucose et des troubles associés
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
EP1986674A4
(fr)
|
2006-02-13 |
2009-11-11 |
Nektar Therapeutics |
Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
|
US7763582B2
(en)
|
2006-02-21 |
2010-07-27 |
University Of Medicine And Dentistry Of New Jersey |
Localized insulin delivery for bone healing
|
EP1996224B1
(fr)
|
2006-03-15 |
2012-11-07 |
Novo Nordisk A/S |
Melanges d'amyline et d'insuline
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
EP2004213A1
(fr)
|
2006-04-03 |
2008-12-24 |
Novo Nordisk A/S |
Agonistes du peptide glp-1
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
US20100087365A1
(en)
|
2006-04-13 |
2010-04-08 |
Roland Cherif-Cheikh |
Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
|
EP2021368A4
(fr)
|
2006-06-08 |
2010-01-20 |
Diabecore Medical Inc |
Oligomères d'insuline dérivés
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
WO2008013938A2
(fr)
|
2006-07-27 |
2008-01-31 |
Nektar Therapeutics |
Formulations de dérivés d'insuline pour administration pulmonaire
|
JP5399244B2
(ja)
|
2006-08-17 |
2014-01-29 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
|
EP2057189B1
(fr)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Composés d'exendine-4 acylée
|
EA200900392A1
(ru)
|
2006-09-07 |
2010-06-30 |
Никомед Гмбх |
Комбинированное лечение сахарного диабета
|
RU2524150C2
(ru)
|
2006-09-22 |
2014-07-27 |
Ново Нордиск А/С |
Аналоги инсулина, устойчивые к протеазам
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
WO2008145323A1
(fr)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Formulation pharmaceutique comprenant des interférons
|
WO2008151736A1
(fr)
|
2007-06-14 |
2008-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Ampoule à deux chambres avec garniture
|
JP2010528792A
(ja)
|
2007-06-14 |
2010-08-26 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
二重チャンバーカルプル
|
EP2173407B1
(fr)
|
2007-07-02 |
2020-02-19 |
Roche Diabetes Care GmbH |
Dispositif pour l'administration de médicaments
|
EP2581441A1
(fr)
|
2007-08-09 |
2013-04-17 |
Genzyme Corporation |
Procédé de traitement d'une maladie auto-immune avec des cellules souches mésenchymateuses
|
CN101778862B
(zh)
|
2007-08-13 |
2014-12-17 |
诺沃-诺迪斯克有限公司 |
快速作用的胰岛素类似物
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
EP2187950A1
(fr)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Utilisation du peptide c de l'insuline, seul ou en combinaison avec glp-1, en tant qu'agent thérapeutique
|
US20090104210A1
(en)
|
2007-10-17 |
2009-04-23 |
Tota Michael R |
Peptide compounds for treating obesity and insulin resistance
|
SI2219607T1
(sl)
|
2007-11-01 |
2012-09-28 |
Merck Serono Sa |
Tekoäśe formulacije lh
|
US8710000B2
(en)
|
2007-11-08 |
2014-04-29 |
Novo Nordisk A/S |
Insulin derivative
|
DK2597103T3
(en)
|
2007-11-16 |
2017-02-13 |
Novo Nordisk As |
Stable pharmaceutical compositions comprising liraglutide and degludec
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
CA2708762A1
(fr)
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation de conjugues de peptides insulinotropes
|
MX2010007342A
(es)
|
2008-01-04 |
2010-08-26 |
Biodel Inc |
Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
|
BRPI0907119A2
(pt)
|
2008-01-09 |
2015-07-14 |
Sanofi Aventis Deutschland |
Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
MY152979A
(en)
|
2008-01-09 |
2014-12-15 |
Sanofi Aventis Deutschland |
Novel insulin derivatives having an extremely delayed time-action profile
|
AU2009211331B2
(en)
|
2008-02-08 |
2014-07-03 |
Theramex HQ UK Limited |
Liquid formulation of FSH
|
EP2240155B1
(fr)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
|
MX2010009033A
(es)
|
2008-02-19 |
2010-12-21 |
Biocon Ltd |
Un metodo para obtener insulinas heterologas purificadas expresadas en levadura.
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
JP2011523052A
(ja)
|
2008-05-23 |
2011-08-04 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Glp−1受容体アゴニスト・バイオアッセイ
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
JP2011526303A
(ja)
|
2008-06-27 |
2011-10-06 |
デューク ユニバーシティ |
エラスチン様ペプチドを含む治療剤
|
US8574214B2
(en)
|
2008-08-30 |
2013-11-05 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge and needle system therefor
|
WO2010028055A1
(fr)
|
2008-09-02 |
2010-03-11 |
Biodel, Inc. |
Insuline dotée d’un profil de libération basal
|
US20100068210A1
(en)
|
2008-09-10 |
2010-03-18 |
Ji Junyan A |
Compositions and methods for the prevention of oxidative degradation of proteins
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
CN106880596A
(zh)
|
2008-10-15 |
2017-06-23 |
精达制药公司 |
高浓缩药物颗粒、制剂、混悬剂及其应用
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
KR101939557B1
(ko)
|
2008-10-17 |
2019-01-17 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린과 glp-1 효능제의 병용물
|
AU2009309623B9
(en)
|
2008-10-30 |
2014-10-02 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Pthの安定化水溶液注射剤
|
UA104605C2
(uk)
*
|
2008-12-15 |
2014-02-25 |
Зіленд Фарма А/С |
Аналоги глюкагону
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
CA2750049C
(fr)
|
2009-02-04 |
2021-02-23 |
Sanofi-Aventis Deutschland Gmbh |
Dispositif medical et procede fournissant des informations utilisables a des fins de regulation de la glycemie
|
CA2752437C
(fr)
|
2009-02-13 |
2017-07-11 |
Boehringer Ingelheim International Gmbh |
Medicaments antidiabetiques
|
EP2435061A4
(fr)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
Composés agonistes du récepteur glp-1 pour amélioration du sommeil
|
BR112012000177B1
(pt)
|
2009-07-06 |
2021-06-01 |
Sanofi-Aventis Deutschland Gmbh |
Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
|
JP5675799B2
(ja)
|
2009-07-06 |
2015-02-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
遅効性インスリン製剤
|
JP2012532177A
(ja)
|
2009-07-06 |
2012-12-13 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
熱及び振動安定性インスリン製剤
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
DK2459171T3
(en)
|
2009-07-31 |
2017-09-25 |
Sanofi Aventis Deutschland |
Long-acting insulin composition
|
US8642548B2
(en)
|
2009-08-07 |
2014-02-04 |
Mannkind Corporation |
Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
ES2398012T5
(es)
|
2009-11-13 |
2020-02-26 |
Sanofi Aventis Deutschland |
Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
|
US20110118178A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
ES2553593T3
(es)
|
2009-11-13 |
2015-12-10 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2
|
AU2010317994B2
(en)
|
2009-11-13 |
2014-03-06 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
CA2685638C
(fr)
|
2009-11-13 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine
|
RU2537239C2
(ru)
|
2009-11-13 |
2014-12-27 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
EP2359843A1
(fr)
|
2010-01-21 |
2011-08-24 |
Sanofi |
Composition pharmaceutique pour le traitement d'un syndrome métabolique
|
KR20130043085A
(ko)
|
2010-02-22 |
2013-04-29 |
케이스 웨스턴 리저브 유니버시티 |
가용성 및 결정 형태의 지속형 인슐린 유사체 제제
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
AR080884A1
(es)
|
2010-04-14 |
2012-05-16 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
WO2011144674A2
(fr)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
Formulation pharmaceutique comprenant de l'insuline glargine et du sbe4-ss-cyd
|
EP2389945A1
(fr)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Composition pharmaceutique comprenant de l'AVE0010 et de l'insuline glargine
|
US9085757B2
(en)
|
2010-06-17 |
2015-07-21 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
WO2012012352A2
(fr)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Peptides et protéines modifiés
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
EP2438930A1
(fr)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Promédicaments comprenant un conjugué de liaison d'exendine
|
KR20130139297A
(ko)
|
2010-10-27 |
2013-12-20 |
노보 노르디스크 에이/에스 |
다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
|
WO2012065996A1
(fr)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
Préparation pharmaceutique contenant de l'insuline glargine et de la maltosyl-ss-cyclodextrine
|
WO2012066086A1
(fr)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
Formulation pharmaceutique comprenant de l'insuline glargine et de la sulfobutyléther-7-ss-cyclodextrine
|
JP2013545782A
(ja)
|
2010-12-14 |
2013-12-26 |
ノヴォ ノルディスク アー/エス |
長時間作用型インスリンと組み合わせた速効型インスリン
|
KR20140041409A
(ko)
|
2011-02-02 |
2014-04-04 |
사노피-아벤티스 도이칠란트 게엠베하 |
2형 진성 당뇨병 환자에서 저혈당증의 예방
|
ES2733646T3
(es)
|
2011-03-11 |
2019-12-02 |
Beth Israel Deaconess Medical Ct Inc |
Anticuerpos anti-CD40 y usos de los mismos
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
RU2623023C2
(ru)
|
2011-05-13 |
2017-06-21 |
Санофи-Авентис Дойчланд Гмбх |
Ликсисенатид и метформин для лечения диабета типа 2
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
CN103906528A
(zh)
|
2011-06-24 |
2014-07-02 |
安米林药品有限责任公司 |
用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
|
JP6367115B2
(ja)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病患者の血糖コントロールに使用する組合せ医薬
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
PT2763690E
(pt)
|
2011-10-04 |
2016-03-23 |
Sanofi Aventis Deutschland |
Lixisenatido para utilização no tratamento de estenose e/ou obstrução no sistema ductal pancreático
|
US20130096059A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
KR101967941B1
(ko)
|
2011-10-28 |
2019-04-10 |
사노피-아벤티스 도이칠란트 게엠베하 |
제2형 당뇨병 치료 프로토콜
|
US20130172244A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
EP2968471B1
(fr)
|
2013-03-01 |
2017-07-19 |
Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca |
Peptides destinés à être utilisés dans le traitement topique de maladies neurodégénératives rétiniennes, en particulier dans les stades précoces de la rétinopathie diabétique et d'autres maladies rétiniennes dans lesquelles la neurodégénérescence joue un rôle essentiel
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
EP2983697B1
(fr)
|
2013-04-03 |
2018-10-31 |
Sanofi |
Traitement du diabète sucré par de nouveaux dosages d'insuline glargine
|
KR102231074B1
(ko)
*
|
2013-06-17 |
2021-03-22 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린 글라진/릭시세나티드 고정비 제형
|
AR098168A1
(es)
|
2013-10-25 |
2016-05-04 |
Sanofi Sa |
Formulación estable de insulina glulisina
|
NZ733670A
(en)
|
2014-12-12 |
2021-12-24 |
Sanofi Aventis Deutschland |
Insulin glargine/lixisenatide fixed ratio formulation
|
TWI706779B
(zh)
|
2015-01-16 |
2020-10-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
小兒第2型糖尿病病患之治療
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|